Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Video Interview: Roche Doubles Down On Immuno-Oncology Trial Collaborations

This article was originally published in Scrip

Executive Summary

Roche partnering exec Jason Coloma explains his company's approach to developing the next wave of immuno-oncology therapies, through collaborations. In the fast-paced, high value world of immuno-oncology development, the number of potential combinations of therapies, including doublet and triplet regimens, is enormous.Recognizing that means you won't have everything in-house and will need to establish external collaborations with a wide range companies, Coloma explains to Emily Hayes, senior editor at Scrip's sister publication, "The Pink Sheet".






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst